Simcyp to Open USA Office to Keep Pace with Global Expansion

Simcyp Limited today announces it is strengthening its presence in the United States and opening an office near Boston, MA.

SHEFFIELD, England--(BUSINESS WIRE)-- Simcyp provides sophisticated modelling and simulation tools for the assessment of pharmacokinetics and pharmacodynamics in virtual populations to a Consortium of leading pharmaceutical and biotechnology clients.

Simcyp will now be represented in the USA by Dr Karen Rowland-Yeo, Senior Scientific Advisor and Principal Consultant at the company. Dr Rowland-Yeo has several years’ experience heading up the Bioinformatics Team at Simcyp and has played a major role in establishing and growing Simcyp Consultancy Services over recent years.

Mr John Evans, Managing Director of Simcyp Limited, commented: “Our specialist team travel all over the world, visiting clients and providing exceptional scientific support. With the recent increase in our client base and volume of consultancy projects, it is now appropriate for Simcyp to have a permanent presence in the US. Our Principal Consultant, Dr Rowland-Yeo is an excellent ambassador for Simcyp and this move increases the proximity of expert assistance to our US clients.”

Commenting on the move, Dr Rowland-Yeo said: “Simcyp already enjoys very close interaction with its clients and is widely recognised for its high quality R&D and scientific support. This move allows us to disseminate Simcyp’s Science to a wider audience and further strengthen client relations.”

– ENDS –

About Simcyp

Simcyp provides platforms for the modelling and simulation of pharmacokinetics and pharmacodynamics in virtual human populations and virtual laboratory animals. The company’s main product the ‘Simcyp Population-based Simulator’ is used by the majority of the world’s global pharmaceutical companies (including Pfizer, Johnson & Johnson and AstraZeneca). The technology allows pharmaceutical researchers to predict in vivo outcomes from routinely generated in vitro data, to fit Simcyp models to observed clinical data and to assess inter-individual variability through ‘real-life’ simulations. This informs decision-making in drug development. Recent advances in Simcyp’s technology include the ability to evaluate drug-drug interactions involving therapeutic proteins – an important development due to the increasing use of biologics and their prominence in multi-drug therapies.

Simcyp also provides expert consultancy services, runs educational workshops and supports academic and drug regulatory research through the provision of not-for-profit simulator licenses to over sixty associate institutions.

For further information please visit www.simcyp.com



CONTACT:

Simcyp Limited
Rebecca Martell
Email: [email protected]
Phone: +44 (0)114 292 2325

KEYWORDS:   United Kingdom  United States  Europe  North America

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.